“AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse”
July 28, 2026
“AstraZeneca’s medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition.
Shares slumped and were on track for the worst day in over six years.
Jefferies analysts said the result didn’t jeopardise the company’s $80 billion sales target by 2030, but said its credibility could take a hit…”
https://www.cnbc.com/2026/07/09/astrazeneca-stock-trial-heart-drug-pharma.html